Selank vs Semax: What the Research Compares

Selank and Semax are near-constant companions in research-peptide discussion — both are synthetic heptapeptides, both carry the same Pro-Gly-Pro C-terminal stabilizing extension, and both come out of the same Russian neuropeptide research tradition. From Selank's side of that comparison, the more useful question is what actually separates the two in the published literature, since the shared motif obscures how differently their studied mechanisms are framed.

A shared stabilizer, different parent peptides

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic analogue of tuftsin, an endogenous tetrapeptide (Thr-Lys-Pro-Arg) associated in the literature with immune-related signaling, extended with the Pro-Gly-Pro tripeptide to resist enzymatic degradation. Semax (Met-Glu-His-Phe-Pro-Gly-Pro), by contrast, is derived from ACTH(4-7), a fragment of adrenocorticotropic hormone that structurally overlaps with alpha-melanocyte-stimulating hormone — placing Semax in the melanocortin peptide family, a lineage Selank does not share.

Because the two parent peptides — tuftsin and ACTH(4-7) — have no structural relationship to each other, the fact that Selank and Semax share a stabilizing tripeptide does not mean they share a mechanism. The Pro-Gly-Pro extension itself has been studied as a potentially active fragment independent of either parent sequence.

Where the studied pathways diverge

Selank's literature is oriented toward the GABAergic system and enkephalin metabolism. Gene-expression studies have reported that Selank produces changes in GABAergic-neurotransmission genes in rat frontal cortex correlated with the changes GABA itself produces, interpreted as an allosteric interaction at the GABA-A receptor complex rather than direct binding. A separate line of research has reported that Selank inhibits enkephalin-degrading enzymes in human serum, a proposed mechanism connecting it to the endogenous opioid signaling system.

Semax's literature is oriented toward neurotrophin expression and melanocortin receptor interactions. Because it derives from ACTH(4-7), published work on Semax has examined neurotrophin gene expression (BDNF, NGF, TrkB) and melanocortin receptors (MC1R–MC5R) in rodent models, particularly in the context of cerebral ischemia-reperfusion research — a research direction that has no clear counterpart in the Selank literature.

Where the two literatures overlap

Despite the mechanistic divergence, a handful of studies have examined both compounds directly, and these represent the clearest comparative data available. An in-vitro serum assay that identified Selank's enkephalin-related activity also tested Semax and reported that both peptides inhibited the enzymes in that assay. A rodent study examined both Selank and Semax in a 6-hydroxydopamine (6-OHDA) model designed to produce Parkinson's-disease-like dopaminergic lesions, comparing behavioral outcomes between the two peptides. And the most direct human comparison comes from a functional-connectivity neuroimaging study in 52 healthy research participants who received Selank, Semax, or placebo, examining regions including the amygdala and dorsolateral prefrontal cortex; the study reported condition-dependent differences in functional connectivity and represents the clearest head-to-head data collected under matched conditions for both compounds.

Human clinical data: a difference in what was studied and where

Selank's human research record includes a published Russian trial in patients with generalized anxiety disorder and neurasthenia examining efficacy and proposed mechanisms, and a separate published study of Selank's immunomodulatory effects in patients with anxiety-asthenic disorders. Semax's human and pre-clinical literature is broader in scope but is oriented toward a different set of endpoints — largely neurotrophin and gene-expression research in ischemia models rather than the anxiety-focused clinical work associated with Selank. Neither compound's human research record approaches the scale of large multi-site pharmaceutical trials, and neither is FDA-approved for any use.

The honest summary

Selank research has been oriented toward GABAergic-system interactions and enkephalin metabolism in pre-clinical and limited clinical models; Semax research has been oriented toward neurotrophin expression and melanocortin-pathway interactions, chiefly in ischemia models. The shared Pro-Gly-Pro motif and shared country-of-origin research tradition explain why the two are discussed together, but the published mechanistic literature for each compound is substantially distinct. Popular shorthand — Selank as "anxiolytic," Semax as "nootropic" — reflects researchers' framing of their respective studied systems, not approved clinical indications.